Zoetis Inc - Company Profile
Powered by 
All the sales intelligence you need on Zoetis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Zoetis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Zoetis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zoetis Inc (Zoetis) is an animal healthcare company. It majorly focuses on the discovery, development, manufacture, and commercialization of parasiticides, vaccines, dermatology treatments, biodevices, anti-infectives, pain and sedation products, and animal health diagnostics. Zoetis serves veterinarians, pet owners, and livestock producers across the world through brands such as Vanguard, Cerenia, Solensia, Apoquel, and VetScan, among others. The company also provides contract manufacturing services and human health products. The company collaborates with third-party veterinary distributors, pharmacies, and e-commerce outlets to distribute its products. It operates manufacturing in the US, Norway, Brazil, Denmark, Belgium, Australia, Spain, Ireland, China, and New Zealand. Zoetis is headquartered in Parsippany, New Jersey, the US.
Headquarters
United States of America
Address
10 Sylvan Way, Parsippany, New Jersey, 07054
Website
www.zoetis.com
Telephone
1 973 8227000
No of Employees
14,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZTS (NYSE)
Revenue (2024)
$9.5B
2.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
7.5%
(2024 vs 2023)
Market Cap*
$30.4B
Net Profit Margin (2024)
XYZ
5.1%
(2024 vs 2023)
* As of and is in US$
Zoetis Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | Vanguard |
| Vaccines | Contract Manufacturing Services | Clavamox |
| Anti-Infectives | Scientific Consulting Services | Convenia |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Product Approvals | In May, the company received approval from the UK’s Veterinary Medicines Directorate (VMD) for Lenivia (izenivetmab injection) for the alleviation of pain associated with osteoarthritis in dogs. |
| 2026 | Contracts/Agreements | In March, the company signed a definitive agreement to acquire the animal genomics business from Neogen Corporation for US$160 million. |
| 2025 | Regulatory Approval | In December, the company received approval from Health Canada for Portela (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. |
Competitor Comparison
| Key Parameters | Zoetis Inc | Elanco Animal Health Inc | Idexx Laboratories Inc | Virbac SA | Boehringer Ingelheim Vetmedica, Inc. |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | United States of America |
| City | Parsippany | Indianapolis | Westbrook | Carros | Ridgefield |
| State/Province | New Jersey | Indiana | Maine | Provence - Alpes- Cote d'Azur | Connecticut |
| No. of Employees | 14,500 | 9,400 | 11,000 | 6,442 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael B. McCallister | Chairman | Executive Board | 2013 | 73 |
| Kristin C. Peck | Chief Executive Officer; Director | Executive Board | 2020 | 54 |
| Wetteny Joseph | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 53 |
| Jeannette Ferran Astorga | Executive Vice President - Corporate Affairs; Chief Sustainability Officer | Senior Management | 2022 | 51 |
| Jamie Brannan | Executive Vice President; Chief Commercial Officer | Senior Management | 2024 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer